A new frontier in Drug Design
We aim to revolutionize the way diseases are diagnosed and treated.
Aptah is a biotech company that aims to support medical advancements by introducing innovative technologies into the drug discovery process.
Through Aptah's technology we are able to modulate the spliceosome machinery and thus, the pre-mRNA, which ensures the precise control of the transcription step and modulation of specific gene expression -not only silencing, but also editing the pre-mRNA by hacking the spliceosome machinery.
Get in touch to learn more.
Aptah is focused on treating and diagnosing tauopathy diseases – diseases associated with protein TAU expression. Microtubule-Associated Protein Tau (MAPT) or TAU, is thought to be a major contributor or cause of certain diseases, known as tauopathies, that are characterized by the deposition of abnormal tau protein inside cells, such as neurons and glial in the brain and breast cells. These disorders include Alzheimer’s disease (AD), Progressive Supranuclear Palsy (PSP), some forms of frontotemporal degeneration (FTD), Glioblastoma, Neuroblastoma and Breast Cancer.
Aptah antisense therapy controls TAU expression inside cells, bringing it to a normal level, which stabilizes the cell’s metabolism. Therefore, we are able to reduce its oxidation, inflammation and reproduction rate.
Click below to learn more about the technology behind Aptah, or get in touch to set up a meeting with us.
Get in Touch
CFL Square Corporate
Florianópolis, Santa Catarina
+55 48 99982-0154